Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - YUMANITY THERAPEUTICS, INC. | d220778dex312.htm |
| EX-31.1 - EX-31.1 - YUMANITY THERAPEUTICS, INC. | d220778dex311.htm |
| EX-10.9 - EX-10.9 - YUMANITY THERAPEUTICS, INC. | d220778dex109.htm |
| 10-Q - FORM 10-Q - YUMANITY THERAPEUTICS, INC. | d220778d10q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report on Form 10-Q of Proteostasis Therapeutics, Inc. (the “Company”) for the period ended June 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Meenu Chhabra, President and Chief Executive Officer (Principal Executive Officer) hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:
| 1) | the Report which this statement accompanies fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| 2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: August 15, 2016 | /s/ Meenu Chhabra | |||||
| Meenu Chhabra President and Chief Executive Officer (Principal Executive Officer) | ||||||
In connection with the quarterly report on Form 10-Q of Proteostasis Therapeutics, Inc. (the “Company”) for the period ended March 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James DeTore, Chief Financial Officer (Principal Financial Officer) hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to my knowledge:
| (1) | the Report which this statement accompanies fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: August 15, 2016 | /s/ James DeTore | |||||
| James DeTore Chief Financial Officer (Principal Financial Officer) | ||||||